Physician profile
Mary E Walsh
NPI 1427135284
$3,170.84
in general payments reported to CMS, 2019-2025
17 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $144 · 2022: $14.78 · 2023: $188 · 2024: $954 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.76 |
| Education | $257.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $429.95 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $408.77 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $393.34 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $389.47 | 2019-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $341.22 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $325.05 | 2019-2025 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $262.47 | 2024-2025 | Cobenfy |
| Abbvie INC. | $164.86 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $159.21 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $83.21 | 2019-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $71.30 | 2024-2025 | Auvelity |
| Indivior INC. | $41.72 | 2019-2020 | |
| Allergan, INC. | $39.94 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.97 | 2024 | Quviviq |
| Owp Pharmaceuticals, INC. | $16.57 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.50 | 2025 | Qelbree |
| Bausch Health US, LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.